{"id":1976,"date":"2014-10-02T21:53:10","date_gmt":"2014-10-02T20:53:10","guid":{"rendered":"https:\/\/sclerodermie.ca\/?p=1976"},"modified":"2024-03-14T10:31:53","modified_gmt":"2024-03-14T14:31:53","slug":"new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension","status":"publish","type":"post","link":"https:\/\/sclerodermie.ca\/en\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\/","title":{"rendered":"Drug approved for the treatment of pulmonary arterial hypertension"},"content":{"rendered":"<p><span style=\"font-size: 14pt;\">Pulmonary arterial hypertension (PAH) is a common, serious complication of Scleroderma which can quickly lead to death if left untreated. Opsumit<sup>\u00ae<\/sup>\u00a0(macitentan) was shown to be effective in reducing morbidity and mortality in adult patients with PAH.<!--more--><\/span><\/p>\n<p><span style=\"font-size: 14pt;\">In November 2013, Health Canada approved Opsumit<sup>\u00ae<\/sup>\u00a0(macitentan) for the long-term treatment of pulmonary arterial hypertension in adults. On October 1<sup>st<\/sup>, 2014, Opsumit<sup>\u00ae<\/sup>\u00a0was added to the List of Medications covered by Quebec&#8217;s basic prescription drug insurance plan which are reimbursed by the\u00a0<em>R\u00e9gie de l\u2019assurance maladie du Qu\u00e9bec<\/em>\u00a0(RAMQ). This means that Opsumit<sup>\u00ae<\/sup>\u00a0will be readily available for patients with PAH covered either by the RAMQ\u2019s Public Prescription Drug Insurance Plan or a private insurer.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Opsumit<sup>\u00ae<\/sup>\u00a0is a valuable option for treating Scleroderma patients with PAH. Scleroderma Quebec is delighted and grateful for the decision of the Government of Quebec.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Here is the link to the \u201cExtract Notice to the Minister\u201d regarding Opsumit<sup>\u00ae<\/sup>\u00a0(i.e. Advice to minister about Opsumit<sup>\u00ae<\/sup>) on the website of the\u00a0<em>Institut national d\u2019excellence en sant\u00e9 et en services sociaux<\/em><em>\u00a0<\/em>(INESSS):<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">\u00a0<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><a href=\"https:\/\/www.inesss.qc.ca\/en\/activites\/drug-products\/drug-products-undergoing-evaluation-and-evaluated\/extract-notice-to-the-minister\/opsumit-1.html\">https:\/\/www.inesss.qc.ca\/en\/activites\/drug-products\/drug-products-undergoing-evaluation-and-evaluated\/extract-notice-to-the-minister\/opsumit-1.html<\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pulmonary arterial hypertension (PAH) is a common, serious complication of Scleroderma which can quickly lead to death if left untreated. Opsumit\u00ae\u00a0(macitentan) was shown to be effective in reducing morbidity and mortality in adult patients with PAH.<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-1976","post","type-post","status-publish","format-standard","hentry","category-non-classe-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Drug approved for the treatment of pulmonary arterial hypertension - Scl\u00e9rodermie Qu\u00e9bec<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sclerodermie.ca\/en\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Drug approved for the treatment of pulmonary arterial hypertension - Scl\u00e9rodermie Qu\u00e9bec\" \/>\n<meta property=\"og:description\" content=\"Pulmonary arterial hypertension (PAH) is a common, serious complication of Scleroderma which can quickly lead to death if left untreated. Opsumit\u00ae\u00a0(macitentan) was shown to be effective in reducing morbidity and mortality in adult patients with PAH.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sclerodermie.ca\/en\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\/\" \/>\n<meta property=\"og:site_name\" content=\"Scl\u00e9rodermie Qu\u00e9bec\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SclerodermieQuebec\" \/>\n<meta property=\"article:published_time\" content=\"2014-10-02T20:53:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-14T14:31:53+00:00\" \/>\n<meta name=\"author\" content=\"sclero\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"sclero\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/sclerodermie.ca\\\/en\\\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sclerodermie.ca\\\/en\\\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\\\/\"},\"author\":{\"name\":\"sclero\",\"@id\":\"https:\\\/\\\/sclerodermie.ca\\\/#\\\/schema\\\/person\\\/edcedd64d9677ca581813c6d89d33ccf\"},\"headline\":\"Drug approved for the treatment of pulmonary arterial hypertension\",\"datePublished\":\"2014-10-02T20:53:10+00:00\",\"dateModified\":\"2024-03-14T14:31:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/sclerodermie.ca\\\/en\\\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\\\/\"},\"wordCount\":198,\"publisher\":{\"@id\":\"https:\\\/\\\/sclerodermie.ca\\\/#organization\"},\"articleSection\":[\"Non class\u00e9\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/sclerodermie.ca\\\/en\\\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\\\/\",\"url\":\"https:\\\/\\\/sclerodermie.ca\\\/en\\\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\\\/\",\"name\":\"Drug approved for the treatment of pulmonary arterial hypertension - Scl\u00e9rodermie Qu\u00e9bec\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sclerodermie.ca\\\/#website\"},\"datePublished\":\"2014-10-02T20:53:10+00:00\",\"dateModified\":\"2024-03-14T14:31:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/sclerodermie.ca\\\/en\\\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/sclerodermie.ca\\\/en\\\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/sclerodermie.ca\\\/en\\\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/sclerodermie.ca\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Drug approved for the treatment of pulmonary arterial hypertension\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/sclerodermie.ca\\\/#website\",\"url\":\"https:\\\/\\\/sclerodermie.ca\\\/\",\"name\":\"Scl\u00e9rodermie Qu\u00e9bec\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/sclerodermie.ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/sclerodermie.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/sclerodermie.ca\\\/#organization\",\"name\":\"Scl\u00e9rodermie Qu\u00e9bec\",\"url\":\"https:\\\/\\\/sclerodermie.ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/sclerodermie.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/sclerodermie.ca\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/logo.png\",\"contentUrl\":\"https:\\\/\\\/sclerodermie.ca\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/logo.png\",\"width\":242,\"height\":115,\"caption\":\"Scl\u00e9rodermie Qu\u00e9bec\"},\"image\":{\"@id\":\"https:\\\/\\\/sclerodermie.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/SclerodermieQuebec\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/sclerodermie.ca\\\/#\\\/schema\\\/person\\\/edcedd64d9677ca581813c6d89d33ccf\",\"name\":\"sclero\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/722505698cad8d43104f707a2241321bbcce440af0007f5832a05640940bda6b?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/722505698cad8d43104f707a2241321bbcce440af0007f5832a05640940bda6b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/722505698cad8d43104f707a2241321bbcce440af0007f5832a05640940bda6b?s=96&d=mm&r=g\",\"caption\":\"sclero\"},\"url\":\"https:\\\/\\\/sclerodermie.ca\\\/en\\\/author\\\/sclero\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Drug approved for the treatment of pulmonary arterial hypertension - Scl\u00e9rodermie Qu\u00e9bec","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sclerodermie.ca\/en\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\/","og_locale":"en_US","og_type":"article","og_title":"Drug approved for the treatment of pulmonary arterial hypertension - Scl\u00e9rodermie Qu\u00e9bec","og_description":"Pulmonary arterial hypertension (PAH) is a common, serious complication of Scleroderma which can quickly lead to death if left untreated. Opsumit\u00ae\u00a0(macitentan) was shown to be effective in reducing morbidity and mortality in adult patients with PAH.","og_url":"https:\/\/sclerodermie.ca\/en\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\/","og_site_name":"Scl\u00e9rodermie Qu\u00e9bec","article_publisher":"https:\/\/www.facebook.com\/SclerodermieQuebec","article_published_time":"2014-10-02T20:53:10+00:00","article_modified_time":"2024-03-14T14:31:53+00:00","author":"sclero","twitter_card":"summary_large_image","twitter_misc":{"Written by":"sclero","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sclerodermie.ca\/en\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\/#article","isPartOf":{"@id":"https:\/\/sclerodermie.ca\/en\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\/"},"author":{"name":"sclero","@id":"https:\/\/sclerodermie.ca\/#\/schema\/person\/edcedd64d9677ca581813c6d89d33ccf"},"headline":"Drug approved for the treatment of pulmonary arterial hypertension","datePublished":"2014-10-02T20:53:10+00:00","dateModified":"2024-03-14T14:31:53+00:00","mainEntityOfPage":{"@id":"https:\/\/sclerodermie.ca\/en\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\/"},"wordCount":198,"publisher":{"@id":"https:\/\/sclerodermie.ca\/#organization"},"articleSection":["Non class\u00e9"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/sclerodermie.ca\/en\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\/","url":"https:\/\/sclerodermie.ca\/en\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\/","name":"Drug approved for the treatment of pulmonary arterial hypertension - Scl\u00e9rodermie Qu\u00e9bec","isPartOf":{"@id":"https:\/\/sclerodermie.ca\/#website"},"datePublished":"2014-10-02T20:53:10+00:00","dateModified":"2024-03-14T14:31:53+00:00","breadcrumb":{"@id":"https:\/\/sclerodermie.ca\/en\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sclerodermie.ca\/en\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/sclerodermie.ca\/en\/new-drug-approved-for-the-treatment-of-pulmonary-arterial-hypertension\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/sclerodermie.ca\/en\/"},{"@type":"ListItem","position":2,"name":"Drug approved for the treatment of pulmonary arterial hypertension"}]},{"@type":"WebSite","@id":"https:\/\/sclerodermie.ca\/#website","url":"https:\/\/sclerodermie.ca\/","name":"Scl\u00e9rodermie Qu\u00e9bec","description":"","publisher":{"@id":"https:\/\/sclerodermie.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sclerodermie.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/sclerodermie.ca\/#organization","name":"Scl\u00e9rodermie Qu\u00e9bec","url":"https:\/\/sclerodermie.ca\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sclerodermie.ca\/#\/schema\/logo\/image\/","url":"https:\/\/sclerodermie.ca\/wp-content\/uploads\/2026\/07\/logo.png","contentUrl":"https:\/\/sclerodermie.ca\/wp-content\/uploads\/2026\/07\/logo.png","width":242,"height":115,"caption":"Scl\u00e9rodermie Qu\u00e9bec"},"image":{"@id":"https:\/\/sclerodermie.ca\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SclerodermieQuebec"]},{"@type":"Person","@id":"https:\/\/sclerodermie.ca\/#\/schema\/person\/edcedd64d9677ca581813c6d89d33ccf","name":"sclero","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/722505698cad8d43104f707a2241321bbcce440af0007f5832a05640940bda6b?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/722505698cad8d43104f707a2241321bbcce440af0007f5832a05640940bda6b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/722505698cad8d43104f707a2241321bbcce440af0007f5832a05640940bda6b?s=96&d=mm&r=g","caption":"sclero"},"url":"https:\/\/sclerodermie.ca\/en\/author\/sclero\/"}]}},"_links":{"self":[{"href":"https:\/\/sclerodermie.ca\/en\/wp-json\/wp\/v2\/posts\/1976","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sclerodermie.ca\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sclerodermie.ca\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sclerodermie.ca\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/sclerodermie.ca\/en\/wp-json\/wp\/v2\/comments?post=1976"}],"version-history":[{"count":3,"href":"https:\/\/sclerodermie.ca\/en\/wp-json\/wp\/v2\/posts\/1976\/revisions"}],"predecessor-version":[{"id":13244,"href":"https:\/\/sclerodermie.ca\/en\/wp-json\/wp\/v2\/posts\/1976\/revisions\/13244"}],"wp:attachment":[{"href":"https:\/\/sclerodermie.ca\/en\/wp-json\/wp\/v2\/media?parent=1976"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sclerodermie.ca\/en\/wp-json\/wp\/v2\/categories?post=1976"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sclerodermie.ca\/en\/wp-json\/wp\/v2\/tags?post=1976"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}